through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028 TG4050, Transgene’s first INTV, demonstrated durable clinical outcomes in resected head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results